Jazz Pharmaceuticals Adds 2% on Q4 Earnings Results
Jazz Pharmaceuticals (NASDAQ: JAZZ) released its Q4 earnings results after the closing bell on Monday. The company reported EPS of $1.17, which compared to analysts' consensus estimates of $1.09.
Revenues for the quarter were $83.5 million versus consensus estimates of $80.84 million.
In Monday's after hours trading session, JAZZ shares are trading up a little better than 2% to $51.70.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.